Madrigal Pharmaceuticals (MDGL) Soared To A New High On Study Results

Madrigal Pharmaceuticals (MDGL) announced Thursday morning that its Phase 2 study of MGL-3196 demonstrated statistical significance in the primary endpoint, the reduction of liver fat.

from RTT - Before the Bell https://ift.tt/2sjLcRV
via IFTTT